News

Zurich, March 2024 | An international CMS team under the lead of Stefan Brunnschweiler and Florian Jung provided comprehensive advice to Ypsomed (SIX: YPSN) on all legal aspects regarding the sale of its pen needle and blood glucose monitoring systems (BGMs) businesses to Medical Technology and Devices S.p.A. (MTD). Ypsomed is supporting a reliable transition to ensure the supply of pen needles to people around the globe who inject insulin and other hormones. During a transition period, Ypsomed will produce pen needles as a contract manufacturer and provide certain services to facilitate a seamless transfer. The production equipment will be gradually moved to the MTD sites by mid-2025. The business with pen needles and BGMs to be transferred to MTD accounted for sales of CHF 52 million in FY 2022/23 and CHF 18 million in the first half of FY 2023/24. The closing of the transaction and thus the transfer of the business with pen needles and blood glucose monitoring systems is expected in summer 2024, after which the transition will begin, and is subject to customary respectively regulatory conditions. Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in busi­ness-to-busi­ness operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners. Ypsomed has over 2,200 employees worldwide. CMS ZurichStefan Brunnschweiler, LL.M., Managing Partner, Head Corporate/M&AFlorian Jung, LL.M., Senior Associate, Corporate/M&ASamuel Felix Gang, LL.M., Senior Associate, Corporate/M&AAnna Mast, Associate, Corporate/M&AAlexander Salamon, Attorney Trainee, Corporate/M&AMarquard Christen, LL.M., MAS, Partner, Com­pet­i­tion­Sophia Rovelli, Attorney Trainee, Com­pet­i­tion­Nad­ine Anwander, Attorney Trainee, CompetitionDr Matthias Kuert, LL.M., Partner, Capital MarketsMark Cagienard, LL.M. VAT, Partner, TaxChristian Gersbach, LL.M., Partner, EmploymentDirk Spacek, LL.M., Partner, IT/IPCMS ParisAlexandra Rohmert, Partner, Corporate/M&AVincent Desbenoit, Associate, Corporate/M&ACaroline Froger-Michon, Partner, Em­ploy­ment­Ca­mille Baumgarten, Associate, Em­ploy­ment­Aliénor Fevre, Counsel, CommercialManon Fleury, Associate, Com­mer­cialJean-Hugues de la Berge, Partner, TaxWilliam Hamon, Partner, TaxCMS FrankfurtDr Heike Wagner, Partner, Corporate/M&ADr Tobias Kilian, Of Counsel, Corporate/M&ADr Reiner Thieme, Associate, Corporate/M&ACMS HamburgDr Heike Wagner, Partner, Corporate/M&A

This year CMS Switzerland has been recommended by The Legal 500 in 21 categories in the European, Middle Eastern and African (EMEA) edi­tion. In addition, 6 of our lawyers are recognized individually for their expertise as "Leading Individuals" or "Next Generation Partner" in the areas of Competition, Insolvency & Corporate Recovery, Insurance, Public Law, Real Estate & Construction and TMT.

Awards & Rankings

Bruker Corporation, a NASDAQ-listed US tech company, entered into a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. The Chemspeed acquisition accelerates Bruker’s entry into lab automation, digitalisation and scientific software solutions. Chemspeed offers modular automation to enhance productivity in R&D and QC departments to achieve more in less time and without additional staff. Chemspeed complements Bruker’s vendor-agnostic plat­form SciY™ for software automation and digital transformation of R&D labs in the life science, biopharma and cleantech industries. An international CMS team headed by Stefan Brunnschweiler and Andrea Relly (Switzerland), in collaboration with the US law firm Nixon Peabody LLP advised Bruker on all legal aspects of the transaction. CMS Switzer­land­Stefan Brunnschweiler, Lead Partner, Corporate / M&AAndrea Relly, Counsel, Corporate / M&ASamuel Gang, Senior Associate, Corporate / M&AAnna Mast, Associate, Corporate / M&AMarquard Christen, Partner, Competition and ComplianceJulia Haas, Senior Associate, Competition and Com­pli­ance­Bernhard Lötscher, Partner, ComplianceSophie Weber, Associate, ComplianceDr Dirk Spacek, Partner, Intellectual PropertyDr Simone Brauch­bar-Birkhäuser, Partner, Intellectual PropertyOlivia Zingg, Associate, Intellectual PropertyMark Cagienard, Partner, TaxJens Lehmann, Senior Associate, TaxMiryam Meile, Senior Associate, Em­ploy­mentSibylle Schnyder, Partner, Real EstateReto Hunsperger, Partner, Com­mer­cialAl­ex­an­der Salamon, Attorney Trainee, Corporate / M&ASophia Rovelli, Attorney Trainee, Corporate / M&AElisabeth Suter, Attorney Trainee, ComplianceCMS BelgiumKai Neuhaus, Partner, Brussel, CompetitionDavid Rappenglück, Associate, Brussel, CompetitionCMS UKRussel Hoare, Partner, Lon­don, Com­pet­i­tion­Claire Barraclough, Associate, Competition

SYNLAB and Sonic have announced the sale of SYNLAB Suisse SA to Sonic Healthcare for a purchase price of CHF 150m, having received the required approval of the Swiss antitrust authority. Closing of the transaction expected for 3 July 2023.

The Swiss business magazine BILANZ, the Handelszeitung, and the magazine PME have awarded the "Top Law Firms" in Switzerland for the 7th time. Out of the 31 legal areas, CMS von Erlach Partners (CMS Switzerland) was ranked as one of the top 25 law firms in Switzerland in 28 areas, which is more than any other law firm in Switzerland. This confirms our position as a leading full-service law firm in the country.

Rankings of CMS Switzerland in The Legal 500 EMEA 2023 Edition

Chambers and Partners has pub­lished its rankings of Europe's lead­ing law firms and lawyers in the Europe Guide 2023. Our firm and our lawyers are listed in both rankings for Switzerland.

Bruker Corporation, a NASDAQ-listed US tech company in the analytical instrumentation sector, invests in Navignostics. Bruker led the CHF 7.5 million seed financing round, which was also joined by Think. Health Ventures, Ventura Biomed Investors and Zürcher Kantonalbank. Navignostics strives to support the selection of targeted and immuno-oncology therapies tailored to the tumour phenotype of individual cancer patients by using artificial intelligence driven software combined with single-cell resolved spatial proteomic tumour data. The funding will strengthen Navignostics' ability to collaborate with clinical, biotechnology and pharmaceutical partners and accelerate the development of its first diagnostic product.A team from CMS Switzerland, led by partner Stefan Brunnschweiler, advised Bruker on all legal matters of the transaction. Bruker is a longstanding CMS client and has been advised by CMS on several acquisitions and disposals in the past. CMS Switzer­land­Stefan Brunnschweiler, Partner, Corporate / M&APascal Stocker, Associate, Corporate / M&ADr Simone Brauchbar Birkhäuser, Counsel, Intellectual PropertyHadi Mirzai, Associate, Life Sciences and CompetitionSarah Keller, Associate, Employment 

Zurich, 28 October 2022The Voigt Group and PHOENIX Pharma Switzerland have agreed to merge their subsidiaries, each active in pharmaceutical logistics and pharmaceutical wholesale sectors respectively, into a 50/50 joint venture. The two long-established and financially sound companies are an ideal fit with complementary offerings and competencies in the supply chain. Subject to approval by the Swiss Competition Commission, this joint venture will create a new, competent and sustainable player in the supply chain of the Swiss healthcare market.A CMS Switzerland team led by Dr Patrick Sommer provided comprehensive legal advice to Voigt Group on this joint venture. CMS Switzerland: Dr. Patrick Sommer, Partner, Lead, Corporate / M&A, Competition & EUAlain Raemy, Partner, Corporate / M&AMarquard Christen, Partner, Competition & EUDirk Spacek, Partner, Intellectual PropertyDr Simone Brauchbar Birkhäuser, Counsel, Intellectual PropertyHadi Mirzai, Associate, Life Sciences, Competition & EUAlexandra Stocker, Associate, Corporate / M&AAnna Mast, Associate, Corporate / M&ADr. Matthias Kuert, Associate, Banking & FinanceThomas Zweifel, Associate, Real EstateChristina Winter, Associate, Employment

Zurich, 22 September 2022The ACE SWISS Group has sold a majority stake of 81% in Casinò Locarno SA to Stadtcasino Baden AG and will retain a 19% stake. Besides Caisnò Locarno, the ACE SWISS Group operates Casino ADMIRAL in Mendrisio. In addition, it also holds minority stakes in other leading Swiss casinos: Casino Bad Ragaz, Casino Interlaken, and Stadtcasino Baden. Under the changed ownership structure, Casino Locarno will submit its application for a B licence at the existing location as part of the reallocation of casino licences.A team led by Stefan Brunnschweiler and Alain Raemy provided comprehensive legal advice to ACE SWISS Group in connection with the transaction. CMS Switzer­land­Stefan Brunnschweiler, Lead, Partner, Corporate / M&AAlain Raemy, Partner, Corporate / M&AMark Cagienard, Partner, TaxMarquard Christen, Partner, Competition & EUAnna Mast, Associate, Corporate / M&ANadine Keller, Train­ee, Corporate / M&A

Diffulivre's successful appeal before the Swiss Supreme Court in the French language books case